Marketing Authorisation (MA) is a siren song for the unprepared. To the uninitiated, it sounds like the final chord of a symphony; in reality, it is the exact moment an orphan asset enters its most dangerous phase of potential value destruction. This is the Ghost Launch, the hollow victory where a therapy is approved and funded on paper, yet remains functionally inaccessible to the patients waiting for it.
Success in rare disease is not a regulatory event; it is an operational one. The Ghost Launch occurs because strategies that succeeded in previous market environments frequently fail to account for the profound complexity of today’s landscape, particularly the last mile of implementation within highly specialised quaternary environments. Here, the gap between a payer’s green light and a patient’s infusion is often measured in years of lost exclusivity and significant erosion of enterprise value (IQVIA, 2024; Analysis Group, 2024).
The rare disease commercialisation landscape has fundamentally transformed. Strategies and expertise that delivered successful launches five years ago now encounter systemic barriers that didn’t previously exist. The fragmentation of the US payer landscape, the evolution of real-world evidence requirements, and the increasing sophistication of health technology assessment have created an environment where historical success is no longer a reliable predictor of future performance.
Many biopharma companies entering the rare disease space are navigating this terrain for the first time. They seek guidance from firms that position themselves as rare disease specialists, organisations that have shepherded multiple products through development and launch with genuine track records. However, there’s a critical distinction often invisible until it’s too late: the difference between expertise built in a previous era versus expertise forged in current complexity.
This isn’t about competence or intent. It’s about unknown unknowns, the challenges you don’t know exist because you’ve never encountered them. When the market environment itself has changed, past success can create false preparedness. The consulting firm that guided ten successful launches under the old paradigm may genuinely believe they understand today’s requirements because their framework worked before. Until they encounter the new barriers, they don’t know what they don’t know.
There’s a phenomenon in rare disease development that doesn’t appear in strategic frameworks: the ability to respond to acute crises with solutions rather than escalations. This capability, the operational scar tissue, comes exclusively from direct experience working within rare disease biopharmaceutical organisations across the entire development and commercialisation continuum.
This isn’t expertise gained from consulting on multiple projects. It’s the cross-functional mastery built from holding operational roles inside the companies that develop and commercialise these therapies, from Quality Assurance to Regulatory Affairs, from Medical Affairs to Market Access, from early development through post-launch management. It’s understanding how these functions interact, where they conflict, and how to navigate both simultaneously when crisis unfolds.
Consider a scenario: A primary manufacturing partner encounters a critical quality deviation three months before commercial launch. Standard project management suggests this becomes a multi-month delay requiring board-level intervention. But to someone who has personally managed CMC operations for orphan products within a biopharmaceutical organisation, this situation activates a different response pattern.
They immediately assess whether the deviation affects released product or only in-process materials. They know which alternative qualified manufacturers might have capacity and which regulatory pathways (Prior Approval Supplement versus Annual Report) apply to different types of changes. They understand that customs clearance for active pharmaceutical ingredients can become a bottleneck and have mitigation strategies ready. Most importantly, they have the professional network to execute solutions in days rather than months, not because they’re better connected, but because they’ve been on the other side of these phone calls.
This isn’t theoretical expertise. Research confirms that successful navigation of orphan drug development can yield operating profit increases of 516% compared to non-orphan peers (PLOS ONE, 2024). However, this multiplier isn’t automatic, it’s the direct result of execution excellence across the entire development and commercialisation continuum, the kind of cross-functional mastery that can only be built within a rare disease biopharmaceutical organisation.
The most valuable capability from end-to-end operational experience within the industry is the ability to reverse-engineer market access requirements into early development decisions. A professional who has managed post-MA commercialisation in quaternary care environments, who has personally navigated getting approved therapies into patients; understands exactly where therapies get stuck. Not in regulatory approval, but in local implementation.
They know that a centre might have national funding approval yet face hospital pharmacy protocols that create months of delay. They understand that administration complexity can become a patient access barrier if not addressed in clinical trial design. They recognise which endpoints will satisfy payer value frameworks years before the pivotal trial reads out (Nature, 2024; McKinsey, 2024).
This is the expertise born from managing Ghost Launch assets back to success, by identifying the institutional barriers post-approval and systematically dismantling them. This foresight allows clinical development architecture to be built alongside the science, rather than discovering market access barriers after approval when the exclusivity clock is already running (PMC, 2024). The window for capturing value in rare disease is narrow; operational readiness must be complete the day of approval, not months after.
The United States market has evolved into a fragmented data maze. Without a singular, formalised HTA process, manufacturers now face simultaneous negotiations with hundreds of individual payers, each requiring bespoke data packages and value justifications (Precedence Research, 2024). This represents a fundamental shift from the environment in which many current specialists built their expertise. Therapies will face delays. The system, in its current form, is not structured for efficiency.
The United Kingdom is emerging as a sophisticated proving ground for adaptive rare disease frameworks. The MHRA’s 2026 Rare Disease Framework, specifically its move towards modular data submissions and Investigational Marketing Authorisations, represents regulatory evolution designed for the current environment (GOV.UK, 2025). This is an extraordinary opportunity, but success requires manufacturers to move beyond traditional vendor relationships and become operational partners capable of generating and managing real-world evidence in real-time (Becaris, 2024).
Here is where European rare disease expertise sits in a league of it’s own. These professionals have managed rare therapies through NICE appraisals, engaged with the MHRA’s evolving frameworks, and operated within nationally coordinated, budgeted healthcare systems. They develop a particular literacy in value justification and understand how to construct real-world evidence packages that satisfy both regulatory rigour and budget impact concerns because they’ve done it under systems demanding integrated data from the start (Oliver Wyman, 2024; Becaris, 2024).
This experience translates directly to navigating current US fragmentation, where manufacturers must now build similar modular, adaptable evidence frameworks for hundreds of individual payers (PM360, 2025). But the crucial distinction: this expertise must come from professionals who built these frameworks whilst working inside biopharmaceutical organisations, not from observing or advising on the process. The cross-functional understanding required to satisfy regulators, payers, and clinicians simultaneously, while managing supply chain, quality systems, and commercial operations, cannot be replicated from the consulting side.
For biopharma companies selecting their strategic partners, the challenge is distinguishing genuine operational expertise from consulting experience. The difference is often invisible in credentials and case studies, but it becomes unmistakable under examination.
Regarding industry experience, the questions are straightforward: How many years did the consultant work within rare disease biopharmaceutical organisations, not merely as a consultant, but as an employee in operational roles? Did they operate at a single level, or did they manage functions across the organisation through post-MA commercialisation, providing a holistic understanding of internal and external development?
The most revealing examination focuses on post-launch reality. Have they personally managed a situation where a therapy is approved and funded, yet the local infrastructure to administer it does not exist? If so, what actions did they take, and what was the duration? Was it a single-site project, or did identifying the initial barriers reveal systemic issues requiring coordinated management across multiple sites? How long did the discovery phase take? How long did each implementation project take from initiation to completion? Were there delays? Did someone go on maternity leave? Did they simply walk into a regional unit and knock on someone’s door?
These aren’t meant to be confrontational questions, they are forensic. The difference between someone who has lived these challenges and someone who has consulted on them becomes immediately apparent in the specificity of their answers. The former will describe the unglamorous, time-consuming, often frustrating operational reality. The latter will describe process frameworks, bespoke service redesign, and strategic approaches.
The stakes are measured in both patient access and commercial performance. Every month of delay between approval and patient infusion is a month of lost exclusivity, a month of eroding enterprise value, and most critically, a month where patients who need the therapy cannot access it. Knowing the road ahead, truly knowing it from having travelled it, provides the efficiency that separates market leaders from Ghost Launches. This is why it is imperative to understand who you are working with and, more importantly, where and how their expertise was actually forged.
Consider a parent whose child shows elite talent in football. Does that parent hire the analyst, or do they seek the professional who has actually played the game? The analyst can explain the theory of how to get out of a corner, but only the professional, the one who has felt the defender’s weight and knows the playbook is just a baseline, can teach the subtle skills required to break free.
In rare disease commercialisation, the stakes are higher. The choice is between expertise built from observing the industry and expertise forged from working within it. As the patent clock ticks, this distinction determines whether an approved therapy becomes a market success or not.
The Ghost Launch is not inevitable. It is the result of a mismatch between the complexity of today’s rare disease landscape and the frameworks being applied to navigate it. Breaking this pattern requires recognising that expertise evolves as markets evolve, and that depth of expertise matters as much as breadth.
For biopharma companies entering the rare disease space, due diligence must extend beyond credentials and case studies to examine where expertise was actually built. The most valuable advisors have held operational roles within rare disease biopharmaceutical organisations, managed the full continuum from development through post-launch commercialisation, and done so recently enough to understand current market dynamics. They are the professionals who have navigated Ghost Launch assets back to success and can reverse-engineer that knowledge into foresight.
The industry is evolving rapidly, and the opportunities, particularly within the UK’s emerging framework, are extraordinary. Success belongs to those who understand that in a transformed landscape, past performance does not guarantee future results. Choose partners who have lived the challenges you are about to face. The difference, in both patient outcomes and commercial performance, is the difference between a market leader and a ghost.
For further discussion or strategic support on navigating these integrated market access pathways, contact us at [email protected]
Analysis Group (2024). The impact of price controls on rare disease medicine access. analysisgroup.com
Becaris (2024). Flexibility in assessment of rare disease technologies via NICE’s STA route. becaris.com
GOV.UK (2025). Rare therapies and UK regulatory considerations: MHRA Policy Paper. gov.uk
IQVIA (2024). From Orphan to Opportunity: Mastering Rare Disease Launch Excellence. iqvia.com
McKinsey & Company (2024). Treating rare diseases: How digital technologies can drive innovation. mckinsey.com
Nature (2024). Strategies for de-risking rare disease programmes during R&D. nature.com
Oliver Wyman (2024). Optimizing Pricing And Access For Rare Disease Drugs. oliverwyman.com
PLOS ONE (2024). Profitability and Market Value of Orphan Drug Companies: A Retrospective Study. journals.plos.org
PM360 (2025). Rare Disease Management Insights: Navigating Payer Challenges. pm360online.com
PMC (2024). Clinical development and marketing application review times for novel orphan drugs. ncbi.nlm.nih.gov
Precedence Research (2024). Cell and Gene Therapy Patient Access and Reimbursement Market Size. precedenceresearch.com
Accelerating Your Innovation’s Journey to Market with our bespoke Accelerator Program.
